Exact Imaging

Exact Imaging is a biotechnology startup based in Canada, founded in 2003. The company is revolutionizing targeted prostate cancer biopsies with its ExactVu™ micro-ultrasound platform, operating at 29 MHz, allowing for real-time imaging and guided biopsies in the urological market. The platform offers high resolution, ease of use, affordability, and integrates seamlessly into the current urological workflow. With regulatory approvals in the European Union, United States, and Canada, including the prestigious CE Mark and FDA 510(k), Exact Imaging's technology has gained wide recognition and acceptance in the market. The company's innovative FusionVu™ application, a micro-US/MRI fusion application, further enhances the precision and accuracy of targeted prostate biopsies, especially in cases where MRI assistance is required. In its latest funding round on 23 March 2021, Exact Imaging secured a substantial amount of $5.10M, attracting investments from key players such as Export Development Canada and the Business Development Bank of Canada. This investment is a testament to the confidence and support of prestigious investors in the startup's groundbreaking technology and its potential to make a significant impact in the field of prostate cancer diagnostics and treatment.